For Older Men, Digital Rectal Exams Continue to Be Important Prostate Screening Tools

Published Online: Thursday, April 18, 2013
Follow Pharmacy_Times:
Despite the fact that an elevated level of prostate-specific antigen (PSA) in the blood has been shown to better predict a positive cancer biopsy result than a digital rectal exam (DRE), the rectal exam is still a necessary screening method for older men with higher, age-adjusted PSA levels, according to a study published in the December 2012 issue of The Canadian Journal of Urology.

Penn State College of Medicine researchers sought to determine the effectiveness of the digital rectal exam in predicting prostate cancer when compared with a PSA test in older men. Because PSA levels naturally increase in men as they age, the researchers were interested in determining how age-specific cutoff rates could contribute to limitations in using the PSA test as the only cancer-screening method.

The researchers studied 806 men undergoing prostate needle biopsy from September 2001 to December 2008. They compared the results of initial testing with biopsy results for each of the participants. Of the 306 men determined to have prostate cancer, 136 had an abnormal DRE. Of the 136 with abnormal DRE results, 43 patients (or 31%) had normal PSA levels for their age.

“Our study confirms that the digital rectal exam remains an important part of screening [such] patients because 31% of cancers in our study would have been missed by using age-specific PSA cutoffs alone,” concluded the study authors.

Related Articles
Bayer HealthCare and Cardinal Health today announced the signing of a 15-year agreement for the contract manufacturing of Xofigo (radium Ra 223 dichloride). As part of the agreement, Cardinal Health will build a state-of-the art, 64,000 square foot facility in Indianapolis, which will be dedicated exclusively to the manufacturing of Xofigo. Product manufactured at this facility will primarily be distributed in the United States and Canada.
ASHP today recognized the work of the late Jerod M. Loeb, Ph.D., a tireless patient safety advocate, with the ASHP Board of Directors Award of Honor. Loeb’s widow, Sherri, accepted the award during the opening session of ASHP’s Midyear Clinical Meeting in Anaheim, CA. Dr. Loeb passed away in 2013 from metastatic prostate cancer.
Contrary to previous evidence, a new study published in The Journal of Urology found that long-term testosterone therapy does not increase the risk of prostate cancer in men with hypogonadism.
Adults aged 50 years or older who feel comfortable about aging are more likely to seek preventive health care services.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times